Mozz, so what we are really saying is there is relatively little risk in both the phase 3 trial or the IP and the main risks lie with the regulatory approvals of the various countries Paradigm wishes to sell the drug.
research reports and media, page-339
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.015(4.84%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 29.5¢ | $86.19K | 286.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 70151 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18600 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |